Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLOPURINOL vs DUZALLO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Gout (management of recurrent uric acid stones),Hyperuricemia associated with malignancy (tumor lysis syndrome),Uric acid nephropathy,Prevention of calcium oxalate calculi in hyperuricosuric patients,Recurrent uric acid stones,Gouty arthritis (prophylaxis of acute attacks),Secondary hyperuricemia (various causes)
Management of signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy),Prevention of tumor lysis syndrome in patients receiving chemotherapy for leukemia, lymphoma, or solid tumor malignancies
100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.
Adults: 200 mg orally twice daily.
Allopurinol: 1–2 hours; oxypurinol: 18–30 hours (prolonged in renal impairment).
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Allopurinol is metabolized primarily by aldehyde oxidase to its active metabolite oxypurinol (alloxanthine), which also inhibits xanthine oxidase. Oxypurinol is further metabolized and eliminated renally.
Primarily metabolized by aldehyde oxidase to oxipurinol, the active metabolite. Also metabolized via xanthine oxidase. Bioactivation requires hepatic metabolism.
Renal: ~76% as unchanged drug and metabolites; oxypurinol (active metabolite) is primarily excreted renally. Biliary/fecal: minor, <5%.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Allopurinol: <1%; oxypurinol: ~50% (mainly to albumin).
Approximately 95% bound primarily to albumin and alpha-1-acid glycoprotein.
Allopurinol: ~1.6 L/kg; distributes into total body water.
Volume of distribution is 0.3–0.5 L/kg, indicating distribution primarily into extracellular fluid and well-perfused tissues.
Oral: ~79–90% for allopurinol; oxypurinol is formed rapidly via first-pass metabolism.
Oral bioavailability is 60%–70% (first-pass metabolism); intravenous bioavailability is 100%.
GFR >50: no adjustment; GFR 10-50: 200 mg/day; GFR <10: 100 mg/day or dosing interval every 48-72 hours.
Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). No dose adjustment required for mild to moderate impairment (e GFR ≥ 30 m L/min/1.73 m²).
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C); consider dose reduction.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C).
Children <6 years: 150 mg/day; 6-10 years: 300 mg/day; 11-16 years: 300-600 mg/day; initial dose 10 mg/kg/day divided in 2-3 doses, max 300 mg/day.
Safety and efficacy not established in pediatric patients (< 18 years).
Start at lowest dose (100 mg/day) and titrate slowly; monitor renal function and adjust per GFR.
No specific dose adjustment required; monitor renal function due to age-related decline.
No FDA black box warning.
There is no FDA black box warning for DUZALLO.
Hypersensitivity reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis) occur more frequently in patients with renal impairment or thiazide diuretic use.,Discontinue at first sign of rash or other signs of hypersensitivity.,Increased risk of bone marrow suppression in patients with renal impairment.,Hepatotoxicity (monitor liver function tests).,Acute gout flare may occur during initiation; prophylaxis with colchicine or NSAIDs recommended.,Dose adjustment required in renal impairment.,Azathioprine or 6-mercaptopurine dose reduction required due to inhibited metabolism.
Hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis,Acute gout flare upon initiation; may require prophylactic anti-inflammatory therapy,Renal impairment: dose adjustment required,Hepatic toxicity may occur,Elevated risk of skin rash with concurrent amoxicillin or ampicillin use
Hypersensitivity to allopurinol or any component of the formulation.,Idiopathic hemochromatosis (relative contraindication due to potential for increased iron storage).,Concurrent use with didanosine (increased risk of pancreatitis and peripheral neuropathy).
Hypersensitivity to allopurinol or any component of the formulation,Concomitant use with didanosine
Avoid high-purine foods such as organ meats (liver, kidney), anchovies, sardines, mussels, and scallops; limit red meat and shellfish; avoid excessive alcohol, especially beer and spirits; maintain adequate fluid intake.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing elagolix levels. High-fat meals may slightly increase elagolix absorption but no dose adjustment needed. No other significant food interactions reported.
FDA Pregnancy Category C. First trimester: limited human data, no clear teratogenic signal; animal studies show fetal anomalies at high doses. Second/third trimester: potential for neonatal complications (e.g., hypersensitivity, rash) if used near term; avoid if possible.
DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if clearly needed.
Excreted in breast milk; M/P ratio ~0.9. Relative infant dose ~1-2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or diarrhea.
Allopurinol and its metabolite oxypurinol are excreted into breast milk. M/P ratio: 1.4 for allopurinol, 2.5 for oxypurinol. No adverse effects reported in infants; compatible with breastfeeding, but monitor infant for rash.
Pregnancy can increase renal clearance and plasma volume, potentially lowering drug levels. Monitor serum uric acid and symptomatic response; dose adjustment may be needed, but data insufficient for specific recommendations. Use lowest effective dose.
No specific dose adjustments recommended for pregnancy. Monitor renal function; reduce dose if creatinine clearance decreases. Standard adult dosing: 100-300 mg/day, may be increased up to 800 mg/day under guidance.
Start at low dose (100 mg/day) and titrate every 2-4 weeks to reduce risk of gout flare; check renal function before dosing and adjust accordingly; allopurinol hypersensitivity syndrome (AHS) is rare but life-threatening, discontinue immediately if rash or signs of hypersensitivity occur; avoid use with azathioprine or 6-mercaptopurine unless dose of these agents is reduced by 60-80%; monitor liver function tests periodically.
DUZALLO (elagolix/estradiol/norethindrone acetate) is a Gn RH antagonist combination product for management of heavy menstrual bleeding in premenopausal women with uterine leiomyomas. Monitor bone mineral density with prolonged use beyond 6 months; avoid in patients with osteoporosis risk factors. Contraindicated with strong CYP3A4 inhibitors and in pregnancy. Assess for mood changes and depression. Use effective non-hormonal contraception during treatment.
Take exactly as prescribed, usually once daily with food.,Do not stop or change dose without consulting your doctor.,Report any rash, hives, itching, or swelling of face/lips immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney stones.,Avoid alcohol, especially beer, as it may increase uric acid levels.,It may take weeks or months to prevent gout attacks; do not skip doses.,During initial therapy, gout attacks may still occur; continue treatment as directed.,Store at room temperature away from moisture and heat.
Take one tablet daily at approximately the same time with or without food.,Missing doses increases risk of pregnancy and reduces effectiveness for bleeding control.,Use effective non-hormonal contraception (e.g., condoms, copper IUD) during treatment and for 2 weeks after discontinuation.,Report severe headache, chest pain, or vision changes immediately (risk of thromboembolic events).,Notify your doctor if you suspect pregnancy or develop heavy bleeding, worsening depression, or jaundice.,Bone density may decrease; calcium and vitamin D supplementation is recommended.,Avoid grapefruit or grapefruit juice during treatment.
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"The combination of allopurinol and captopril increases the risk of hypersensitivity reactions, including Stevens-Johnson syndrome and angioedema, due to a pharmacodynamic interaction that potentiates immune-mediated adverse effects. This is particularly concerning in patients with renal impairment, where both drugs may accumulate, and can lead to severe cutaneous adverse reactions or hematologic toxicities."
"Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purine analogs. Tegafur is a prodrug of 5-fluorouracil and is metabolized via the same pathway. Coadministration of allopurinol may reduce the conversion of tegafur to its active metabolite, thereby decreasing the therapeutic efficacy of tegafur. This can lead to suboptimal antineoplastic effect and potential treatment failure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLOPURINOL vs DUZALLO, answered by our medical review team.
ALLOPURINOL is a Xanthine Oxidase Inhibitor that works by Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.. DUZALLO is a Xanthine Oxidase Inhibitor that works by DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLOPURINOL and DUZALLO depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLOPURINOL is: 100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.. The standard adult dose of DUZALLO is: Adults: 200 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLOPURINOL and DUZALLO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLOPURINOL is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data, no clear teratogenic signal; animal studies show fetal anomalies at high doses. Second/third trimester: potential for. DUZALLO is classified as Category C. DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.